Rescriptor

Rescriptor is a brand name of delavirdine, approved by the FDA in the following formulation(s):

RESCRIPTOR (delavirdine mesylate - tablet; oral)

• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: April 4, 1997
  
  Strength(s): 100MG
  


• 
  Manufacturer: VIIV HLTHCARE
  
  Approval date: July 14, 1999
  
  Strength(s): 200MG ^[RLD]

Has a generic version of Rescriptor been approved?

No. There is currently no therapeutically equivalent version of Rescriptor available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rescriptor. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Diaromatic substituted compounds as anti-HIV-1 agents
  Patent 5,563,142
  Issued: October 8, 1996
  Inventor(s): Palmer; John R. & Romero; Donna L. & Aristoff; Paul A. & Thomas; Richard C. & Smith; Herman W.
  Assignee(s): The Upjohn Company
  The present invention includes diaromatic substituted heterocyclic compounds (III) ##STR1## which are useful in treating individuals infected with the HIV virus.
  
  Patent expiration dates:
  
  
  • October 8, 2013
    
  
  



• 
  Delavirdine high strength tablet formulation
  Patent 6,177,101
  Issued: January 23, 2001
  Inventor(s): Martino; Alice C. & Bates; Ashley H. & Morozowich; Walter & Lee; E. John
  Assignee(s): Pharmacia & Upjohn Company
  Disclosed is a non-sustained release pharmaceutical tablet composition which comprises a rapidly precipitating drug in an amount from about 5 to about 60% and at least one member selected from the group consisting of a binder in an amount of from about 2 to about 25% and a superdisintegrant in an amount from about 6 to about 40% where the rapidly precipitating drug, "binder" and superdisintegrant are mixed and compressed into a tablet without heating, solvent or grinding.
  
  Patent expiration dates:
  
  
  • June 7, 2019
    
  
  

See also...

• Rescriptor Consumer Information (Wolters Kluwer)
• Rescriptor Consumer Information (Cerner Multum)
• Rescriptor Advanced Consumer Information (Micromedex)
• Rescriptor AHFS DI Monographs (ASHP)
• Delavirdine Consumer Information (Wolters Kluwer)
• Delavirdine Consumer Information (Cerner Multum)
• Delavirdine Advanced Consumer Information (Micromedex)
• Delavirdine Mesylate AHFS DI Monographs (ASHP)